Preliminary evidence from case reports and early phase clinical trials indicates that immunotherapy may be effective in a subset of NF1-associated MPNST, but robust biomarkers are needed to identify patients most likely to respond to this treatment. The gene discussed is NF1; the disease is malignant peripheral nerve sheath tumor.